Revenue and Profit Performance - Revenue for the first three quarters of 2024 reached RMB 16,232,148,089, an increase of 1.19% year-over-year[2] - Net profit attributable to shareholders of the listed company for the first three quarters of 2024 was RMB 630,147,823, a decrease of 12.06% year-over-year[2] - Revenue for the first three quarters of 2024 reached 16.232 billion yuan, a year-on-year increase of 1.19%[14] - Net profit attributable to shareholders of the listed company for the first three quarters of 2024 was 630 million yuan, a year-on-year decrease of 12.06%[14] - Total revenue for the first three quarters of 2024 reached RMB 16,232,148,089, a slight increase from RMB 16,041,526,841 in the same period of 2023[36] - Net profit attributable to parent company shareholders reached 630,147,823 yuan, a decrease from 716,560,499 yuan in the same period last year[37] - Total operating revenue for the first three quarters of 2024 was 18,599,452,504 yuan, compared to 18,265,401,747 yuan in the same period of 2023[39] Cash Flow and Financial Position - Net cash flow from operating activities for the first three quarters of 2024 was RMB 1,255,721,494, a decrease of 12.14% year-over-year[3] - Total assets as of the end of the third quarter of 2024 were RMB 21,211,311,937, a slight decrease of 0.09% compared to the end of the previous year[3] - Equity attributable to shareholders of the listed company as of the end of the third quarter of 2024 was RMB 6,961,742,913, an increase of 3.89% compared to the end of the previous year[3] - Net cash flow from operating activities was 1,255,721,494 yuan, down from 1,429,230,229 yuan in the previous year[39] - Total assets as of September 30, 2024, were RMB 21,211,311,937, slightly down from RMB 21,230,999,976 at the end of 2023[34] - Total liabilities as of September 30, 2024, were RMB 13,663,251,217, a decrease from RMB 13,941,960,115 at the end of 2023[35] - Shareholders' equity increased to RMB 7,548,060,720 as of September 30, 2024, up from RMB 7,289,039,861 at the end of 2023[35] - Cash and cash equivalents stood at RMB 2,099,006,221 as of September 30, 2024, up from RMB 1,974,984,513 at the end of 2023[32] - Inventory decreased to RMB 3,741,313,824 as of September 30, 2024, from RMB 4,152,484,967 at the end of 2023[32] - Long-term equity investments increased to RMB 85,220,294 as of September 30, 2024, up from RMB 67,821,191 at the end of 2023[34] - Cash and cash equivalents at the end of the period were 950,194,621 yuan, down from 1,028,321,991 yuan at the end of the previous year[41] - Total cash inflow from financing activities was 2,026,845,742 yuan, up from 1,100,273,193 yuan in the previous year[40] - Total cash outflow from investment activities was 464,461,047 yuan, compared to 706,820,762 yuan in the same period last year[40] - Net cash flow from investment activities was -439,382,336 yuan, compared to -343,615,820 yuan in the previous year[40] Store Operations and Expansion - The company had 15,591 stores as of September 30, 2024, including 10,300 directly operated stores and 5,291 franchised stores[19] - In the first three quarters of 2024, the company added 2,368 new stores, including 1,264 directly operated stores and 1,104 franchised stores[19] - The company closed 351 stores in the first three quarters of 2024, including 144 directly operated stores and 207 franchised stores[19] - Total number of stores reached 15,591, including 10,300 directly operated stores and 5,291 franchised stores[24] - In Q3 2024, the company added 2,368 new stores, with 1,264 directly operated stores and 1,104 franchised stores[24] - The company completed 3 acquisition projects in the reporting period, totaling 41 stores with a combined amount of 40.46 million yuan[22] - The company's stores in prefecture-level cities and below accounted for 77% of the total, with 80% of new stores in 2024 located in these areas[24] - The average preparation cycle for new directly operated stores in Q3 2024 was 40 days, a reduction of 5 days compared to the same period last year[24] Gross Profit and Margin - Gross profit margin for the first three quarters of 2024 was 33.87%, an increase of 1.36 percentage points year-on-year[14] - Revenue from retail business in the first three quarters of 2024 was 13.314 billion yuan, with a gross profit margin of 38.03%[15] - Revenue from the Chinese medicine business in the first three quarters of 2024 was 1.204 billion yuan, with a gross profit margin of 45.08%[17] - Revenue from non-drug products in the first three quarters of 2024 was 2.057 billion yuan, with a gross profit margin of 39.53%[17] - The gross profit margin for the first three quarters of 2024 was 33.87%, an increase of 1.36 percentage points year-on-year[25] - The company's promotional gross profit ROI was 1.49 in Q3 2024, a year-on-year increase of 6.1%[28] Online and Digital Performance - The company's online channel sales (including franchise) reached approximately 1.74 billion yuan in the first three quarters of 2024, a year-on-year increase of 16%[27] - The company's O2O and B2C sales rankings were fifth and third in the market, respectively, in Q3 2024[27] - The private domain mini-program sales increased by 22.6% year-on-year in Q3 2024, with DAU increasing by 118%[27] - The company has 12,555 O2O delivery service stores and 728 24-hour stores as of the end of the reporting period[27] - The total number of company members reached 97.17 million, with 14.65 million active members in Q3 2024 and over 3.1 million new registered members[27] Shareholder and Equity Information - The company's top shareholder, Laobaixing Pharmaceutical Group Co., Ltd., holds 26.12% of the shares, with 123,204,000 shares pledged[10] - Equity attributable to shareholders of the listed company as of the end of the third quarter of 2024 was RMB 6,961,742,913, an increase of 3.89% compared to the end of the previous year[3] - Shareholders' equity increased to RMB 7,548,060,720 as of September 30, 2024, up from RMB 7,289,039,861 at the end of 2023[35] Earnings and Return on Equity - Basic earnings per share for the third quarter of 2024 were RMB 0.17, a decrease of 37.31% year-over-year, primarily due to the decline in net profit attributable to shareholders[9] - The company's weighted average return on equity (ROE) for the first three quarters of 2024 was 9.14%, a decrease of 1.58 percentage points year-over-year[3] - Basic earnings per share (EPS) for the quarter were 0.83 yuan, compared to 0.94 yuan in the same period last year[38] - Total comprehensive income for the period was 743,726,347 yuan, a decrease from 820,172,473 yuan in the previous year[38] Non-Recurring Items and Impairment - Non-recurring gains and losses for the first three quarters of 2024 amounted to RMB 23,069,846, including government subsidies and gains from financial assets[6] - Total assets impairment loss was -10,447,829 yuan, compared to -2,659,467 yuan in the same period last year[37] Chronic Disease Management and Brand Exposure - The company's chronic disease management services have accumulated over 16.84 million records, 90.5 million self-tests, and 37.36 million follow-ups as of the end of the reporting period[30] - The company's brand exposure exceeded 1.4 billion times annually, with over 77.97 million views of brand videos on the self-media matrix in Q3 2024[31] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 15,333,787,742, compared to RMB 15,075,343,081 in the same period of 2023[36] - Sales expenses increased to RMB 3,577,910,985 in the first three quarters of 2024, up from RMB 3,355,680,232 in the same period of 2023[36] - Management expenses rose to RMB 825,589,932 in the first three quarters of 2024, compared to RMB 703,469,470 in the same period of 2023[36] Inventory and Turnover - The inventory turnover days in Q3 2024 were 98 days, a decrease of 5 days year-on-year[25] - Inventory decreased to RMB 3,741,313,824 as of September 30, 2024, from RMB 4,152,484,967 at the end of 2023[32] Franchise and Alliance Business - The company's franchised business achieved a distribution sales volume of 1.639 billion yuan, a year-on-year increase of 7.5%[24] - The alliance business achieved a distribution sales volume of 280 million yuan, a year-on-year increase of 90.8%[24] Self-Owned Brand and Sales - The company's self-owned brand sales in directly operated stores reached 2.53 billion yuan, accounting for 21.9% of total sales, an increase of 2.4 percentage points year-on-year[25] Outpatient and Internet Prescription Services - The company has 5,347 stores (including 4,170 directly operated and 1,177 franchise) with outpatient coordination qualifications, accounting for 40.49% of directly operated stores[26] - The company has 4,191 stores (including 3,384 directly operated and 807 franchise) that can use internet prescriptions, accounting for 32.85% of directly operated stores[26]

证券代码：603883 证券简称：老百姓 公告编号：2024-068 老百姓大药房连锁股份有限公司 第五届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 （2）公司2024年第三季度的内容和格式符合中国证监会和上海证券交易所 的有关规定和要求，所包含的信息能全面、真实地反映公司在报告期内的经营 和财务管理状况。 一、监事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2024 年 10 月 19 日 发出召开第五届监事会第五次会议的通知，会议于 2024 年 10 月 29 日以现场方 式召开。会议应参与表决的监事 3 名，实际参与表决的监事 3 名。本次会议经 过了适当的通知程序，会议程序符合《中华人民共和国公司法》等有关法律法 规及《公司章程》的规定，会议及通过的决议合法有效。 二、监事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于公司 2024 年第三季度报告的议案》 监事会认为： （1）公司2024年第三季度报告编制和审议符合法律、法规、《公司章程》 和 ...

证券代码：603883 证券简称：老百姓 公告编号：2024-069 老百姓大药房连锁股份有限公司 关于变更部分募集资金用途的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 重要内容提示： 老百姓大药房连锁股份有限公司（以下简称"公司"或"老百姓"）基于项 目实施情况和公司需求，经公司谨慎研究决策，为提升募集资金使用效率，拟将 原募集资金投资项目（以下简称"募投项目"）"企业数字化平台及新零售建设 项目"部分募集资金 6,600 万元用于实施新项目"老百姓大药房长沙 NDC 扩建 项目（一期）"。 "老百姓大药房长沙 NDC 扩建项目（一期）"总投资金额为 12,816 万元， 建设期 18 个月。 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"证监会"）《关于核准老百姓大药 房连锁股份有限公司非公开发行股票的批复》（证监许可[2021]2294 号）核准， 公司以非公开发行股票方式向特定投资者发行人民币普通股（A 股），募集资金 1/9 总额为人民币 1,740,453,673.80 元，扣除不含税发行费 ...

证券代码：603883 证券简称：老百姓 公告编号：2024-067 老百姓大药房连锁股份有限公司 第五届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2024 年 10 月 19 日发出召开第五届董事会第五次会议的通知，会议于 2024 年 10 月 29 日在公司 会议室以现场加通讯表决方式召开，本次董事会应参加表决的董事 9 名，实际 参加表决的董事 9 名。本次董事会由董事长谢子龙先生主持，董事会秘书等相 关人员列席会议。本次会议经过了适当的通知程序，会议程序符合有关法律法 规及《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 本议案已经公司第五届董事会战略与ESG委员会第二次会议审议通过，尚需 股东大会审议通过。 （一）审议通过《关于公司 2024 年第三季度报告的议案》 根据《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规及 《公司章程》等规章制度， ...

证券代码：603883 证券简称：老百姓 公告编号：2024-079 老百姓大药房连锁股份有限公司 一、 召开会议的基本情况 关于召开 2024 年第三次临时股东大会的通知 (一) 股东大会类型和届次 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年第三次临时股东大会 重要内容提示： 召开的日期时间：2024 年 11 月 15 日 15 点 30 分 召开地点：湖南省长沙市开福区青竹湖路 808 号老百姓 15 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 股东大会召开日期：2024年11月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 11 月 15 日至 2024 年 11 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投 ...

证券代码：603883 证券简称：老百姓 公告编号：2024-075 老百姓大药房连锁股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 重要内容提示： ● 老百姓大药房连锁股份有限公司（以下简称"公司"）本次使用闲置募 集资金暂时补充流动资金的金额为不超过人民币 15,000 万元。 ● 公司募集资金暂时补充流动资金的使用期限：自公司董事会审议通过之 日起不超过 6 个月。 注：募集资金拟投入补充流动资金的金额已扣除 1,517.97 万元发行费用。 三、公司前次使用闲置募集资金暂时补充流动资金的情况 ● 公司于 2024 年 10 月 29 日召开第五届董事会第五次会议和第五届监事 会第五次会议审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议 案》，同意公司使用不超过 15,000 万元暂时闲置的募集资金暂时补充流动资金。 现将相关事宜公告如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准老百姓 大药房连锁股份有限公 ...

二、募集资金使用情况 截至 2024 年 9 月 30 日，公司非公开发行股票募集资金余额为 30,557.15 万元（包 含利息、手续费以及发行费用的影响），具体使用情况如下表所示： 高盛（中国）证券有限责任公司 关于老百姓大药房连锁股份有限公司 变更部分募集资金用途的核查意见 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所 上市公司自律监管指引第 11 号——持续督导》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》等有关法律法规和规范性文件的要求，高盛（中国）证券有限责 任公司（以下简称"高盛中国"或"保荐机构"）作为老百姓大药房连锁股份有限公司 （以下简称"老百姓"或"公司"）2021 年度非公开发行 A 股股票的保荐机构，就老百 姓拟变更部分募集资金用途的情况进行了专项核查，并发表如下核查意见： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准老百姓大药 房连锁股份有限公司非公开发行股票的批复》（证监许可[2021]2294 号）核准，公司以 非 ...

关于老百姓大药房连锁股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所 上市公司自律监管指引第 11 号——持续督导》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》等有关法律法规和规范性文件的要求，高盛（中国）证券有限责 任公司（以下简称"高盛中国"或"保荐机构"）作为老百姓大药房连锁股份有限公司 （以下简称"老百姓"或 "公司"）2021 年度非公开发行 A 股股票的保荐机构，就老 百姓使用部分闲置募集资金暂时补充流动资金的情况进行了专项核查，并发表如下核 查意见： 一、募集资金基本情况 高盛（中国）证券有限责任公司 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准老百姓大药 房连锁股份有限公司非公开发行股票的批复》（证监许可[2021]2294 号）核准，公司以 非公开发行股票方式向特定投资者发行人民币普通股（A 股），募集资金总额为人民币 1,740,453,673.80 元，扣除不含税发行费用人民币 15,17 ...

重要内容提示： 本次首次授予部分第二个解除限售期符合解除限售条件的激励对象共计 236人，可解除限售的限制性股票数量为764,501股，占目前公司总股本 76,023.1174万股的0.101%。 证券代码：603883 证券简称：老百姓 公告编号：2024-070 老百姓大药房连锁股份有限公司 关于 2022 年限制性股票激励计划首次授予部分 第二个解除限售期及预留授予第一个解除限售期 解除限售条件成就但股票暂不上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次预留授予部分第一个解除限售期符合解除限售条件的激励对象共计 57人，可解除限售的限制性股票数量为209,002股，占目前公司总股本76,023.1174 万股的0.027%。 根据公司《2022年限制性股票激励计划（草案）》所有激励对象承诺， 自每个解除限售的条件达成之日起6个月内，其所持有的当批次解除限售的全部 限制性股票不得转让。因此公司申请本次解除限售的限制性股票暂不上市，首次 授予部分继续禁售至2025年3月28日，预留授予部分继续禁售至2025 ...

关于老百姓大药房连锁股份有限公司 2022 年限制性股票激励计划首次授予部分第二个解除 限售期及预留授予部分第一个解除限售期解除限售条 件成就但股票暂不上市、回购注销部分限制性股票、调 整回购价格及回购数量的 法律意见书 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：（0731）82953-778 传真：（0731）82953-779 网站：www.qiyuan.com 致：老百姓大药房连锁股份有限公司 湖南启元律师事务所（以下简称"启元"或"本所"）接受老百姓大药房连 锁股份有限公司（以下简称"老百姓""公司"或"上市公司"）的委托，担任 老百姓 2022 年限制性股票激励计划（以下简称"本次激励计划""本激励计划" 或"激励计划"）的专项法律顾问。 湖南启元律师事务所 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理 办法》（以下简称"《管理办法》"）等现行法律、法规和规范性文件以及《老 百姓大药房连锁股份有限公司章程》（以下简称"《公司章程》"）、《老百姓 大药房连锁股份有限 ...